Bayer Korea has been ordered to divest its oral contraceptives business, chiefly its Mercilon (ethinylestradiol) drug, which it acquired when its Germany parent Bayer bought Merck's consumer-care business recently.
Bayer has already said it plans to home in on life sciences after it carves out its plastics unit later this year for an IPO or spinoff. So what, exactly, does that mean for its HealthCare division, numbers-wise?
As it prepares to streamline itself and rebrand as a life-sciences-focused company, Bayer is counting on colorectal cancer drug Stivarga to chip in to its sales haul--big time. But the drug can only go so far if people don't get checked for the lethal cancer.
Want Sovaldi (sofosbuvir), the hepatitis C drug selling in the United States for $1,000 per pill, for just $10 a pill? Go to Bangladesh or some other country where the drug is about to be produced and sold free of the control of Sovaldi's owner, Gilead Sciences.
Bayer Healthcare said it plans to sell its animal health production facility in St. Joseph, MO, and some of the products manufactured at the plant.
Bayer said earlier this week that it would be counting on eye blockbuster Eylea to provide some serious sales growth in 2015, and now, it has a new indication the company hopes can help it get there.
Bayer's new pharma launches may be soaring, but that wasn't enough to help the German drugmaker meet analysts' profit estimates for Q4. For 2015, the company expects bigger things--but as it moves forward with plans to bid farewell to its plastics unit and competition ramps up for its best-sellers, its consumer health division will need to start pulling its weight.
Bayer is reportedly near a deal to sell its diabetes device business to KKR-backed Panasonic Healthcare for up to €2 billion ($2.3 billion).
With the hire of Bayer's Olivier Brandicourt as its new CEO, Sanofi will fill the hole it created when it ousted helmsman Chris Viehbacher nearly four months ago. But that means another leadership change is afoot at Brandicourt's current company, which is already in the middle of plenty of shuffling at the top.
Bayer is slated to sell its diabetes devices business to Panasonic Healthcare, according to a report from Bloomberg. The move has been years in the making as Bayer works to sell off peripheral businesses to focus on its core profitable ones.